Seizert Capital Partners LLC Acquires Shares of 14,883 Bioventus Inc. (NYSE:BVS)

Seizert Capital Partners LLC acquired a new stake in Bioventus Inc. (NYSE:BVS) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 14,883 shares of the company’s stock, valued at approximately $156,000.

A number of other institutional investors also recently added to or reduced their stakes in BVS. Principal Financial Group Inc. lifted its position in shares of Bioventus by 9.4% during the 4th quarter. Principal Financial Group Inc. now owns 19,228 shares of the company’s stock valued at $202,000 after acquiring an additional 1,652 shares during the period. Virtus Fund Advisers LLC acquired a new stake in shares of Bioventus during the 3rd quarter valued at approximately $42,000. Plato Investment Management Ltd acquired a new stake in shares of Bioventus during the 4th quarter valued at approximately $38,000. Quest Partners LLC acquired a new stake in shares of Bioventus during the 3rd quarter valued at approximately $51,000. Finally, Quarry LP acquired a new stake in shares of Bioventus during the 3rd quarter valued at approximately $59,000. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Insider Buying and Selling at Bioventus

In other news, SVP Katrina J. Church sold 2,535 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $10.53, for a total transaction of $26,693.55. Following the completion of the sale, the senior vice president now directly owns 47,264 shares of the company’s stock, valued at $497,689.92. The trade was a 5.09 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Robert E. Claypoole sold 28,786 shares of the business’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $9.10, for a total transaction of $261,952.60. Following the sale, the chief executive officer now directly owns 64,964 shares of the company’s stock, valued at $591,172.40. This represents a 30.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 52,932 shares of company stock worth $512,511. Insiders own 32.90% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on BVS. JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and lifted their price objective for the stock from $12.00 to $13.00 in a research report on Tuesday, December 17th. Canaccord Genuity Group lifted their price objective on Bioventus from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th.

Bioventus Trading Up 1.0 %

Shares of BVS opened at $10.19 on Thursday. The stock has a fifty day moving average of $10.22 and a two-hundred day moving average of $10.99. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The company has a market capitalization of $826.97 million, a PE ratio of -16.70 and a beta of 0.86. Bioventus Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.38.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.